Crescendo Biologics develops potent, multi-functional Humabody® therapeutics with a focus on novel targeted T-cell engagement.
Using our proprietary transgenic mouse platform, we have created a tumour-targeted T-cell engager mechanism capable of activating T-cells only in the tumour microenvironment. Our ability to configure unique therapeutic formats allows Humabodies to engage targets in ways that generates new biology through novel target engagement.
Our transgenic VH platform enables us to create an almost limitless number of mono- and multi-functional constructs capable of engaging therapeutically valuable targets in a way that is fundamentally different to whole antibodies.
Using our formatting and development expertise, we produce highly potent optimally configured therapeutics by using differentiated approaches such as:
- combinatorial specificity/functionality
- bi-paratopic targeting
- tuneable internalisation
- extended half-life.
Our unique tumour-targeted T-cell engagers deliver safe, highly potent cancer killing by activating only tumour-specific T-cells within the tumour microenvironment. Their superior biodistribution through minimal size, enhanced tissue penetration and tumour accumulation has the potential to deliver greatly improved therapeutic index through both enhanced safety and potency.
Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody®
/in homepage, News /by Carly KingCrescendo Biologics announces early licensing by Takeda
of first oncology-targeted Humabody®
View PDF
Crescendo Biologics wins “Biotech Company of the Year” at the Cambridge Independent Science and Technology Awards 2018
/in homepage, News /by Carly KingCrescendo Biologics wins “Biotech Company of the Year” at the Cambridge Independent Science and Technology Awards 2018
View PDF
Crescendo Biologics appoints SVP CMC, Dr Richard Williams, and new CDMO partner, as it advances towards the clinic
/in homepage, News /by Carly KingCrescendo Biologics appoints SVP CMC, Dr Richard Williams, and new CDMO
partner, as it advances towards the clinic
View PDF